VRDN

Viridian Therapeutics
VRDN

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
$1.30B
EV
$871.04M
Shares Outstanding
81.62M
Beta
0.46

Wall Street View

Analyst Rating
OUTPERFORM
Analyst Target Price
$38.31
P/E 2025E
-
P/Revenue 2025E
-

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Viridian Therapeutics, Inc.

gainify
VRDN

Viridian Therapeutics, Inc.

VRDN

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company’s product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical tr...

Sector

Healthcare

Industry

Biotechnology

CEO

Mahoney, Stephen

Employees

143

IPO Date

2014-06-18

Headquarters

221 Crescent Street, Suite 401, Waltham, Massachusetts, 02453, United States

gainify
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on Trustpilot
powered-by-sp

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.